Published in Nature on June 24, 2010
GENCODE: the reference human genome annotation for The ENCODE Project. Genome Res (2012) 19.19
Molecular mechanisms of long noncoding RNAs. Mol Cell (2011) 11.44
A ceRNA hypothesis: the Rosetta Stone of a hidden RNA language? Cell (2011) 10.50
A long noncoding RNA controls muscle differentiation by functioning as a competing endogenous RNA. Cell (2011) 9.24
Natural RNA circles function as efficient microRNA sponges. Nature (2013) 8.93
Circular RNAs are a large class of animal RNAs with regulatory potency. Nature (2013) 8.54
The functions and regulation of the PTEN tumour suppressor. Nat Rev Mol Cell Biol (2012) 7.32
Coding-independent regulation of the tumor suppressor PTEN by competing endogenous mRNAs. Cell (2011) 7.02
The functional role of long non-coding RNA in human carcinomas. Mol Cancer (2011) 6.37
Roles for microRNAs in conferring robustness to biological processes. Cell (2012) 6.32
The emergence of lncRNAs in cancer biology. Cancer Discov (2011) 6.32
miRNAs in human cancer. J Pathol (2010) 6.02
Molecular genetics of prostate cancer: new prospects for old challenges. Genes Dev (2010) 5.83
An extensive microRNA-mediated network of RNA-RNA interactions regulates established oncogenic pathways in glioblastoma. Cell (2011) 5.75
The hallmarks of cancer: a long non-coding RNA point of view. RNA Biol (2012) 5.60
Long non-coding RNAs: new players in cell differentiation and development. Nat Rev Genet (2013) 5.48
MicroRNAs and their targets: recognition, regulation and an emerging reciprocal relationship. Nat Rev Genet (2012) 5.38
Circular RNAs are the predominant transcript isoform from hundreds of human genes in diverse cell types. PLoS One (2012) 5.28
In vivo identification of tumor- suppressive PTEN ceRNAs in an oncogenic BRAF-induced mouse model of melanoma. Cell (2011) 5.19
Circular RNAs are abundant, conserved, and associated with ALU repeats. RNA (2012) 5.16
Structure and function of long noncoding RNAs in epigenetic regulation. Nat Struct Mol Biol (2013) 4.57
The microcosmos of cancer. Nature (2012) 4.50
starBase v2.0: decoding miRNA-ceRNA, miRNA-ncRNA and protein-RNA interaction networks from large-scale CLIP-Seq data. Nucleic Acids Res (2013) 4.33
Mapping the human miRNA interactome by CLASH reveals frequent noncanonical binding. Cell (2013) 4.28
Expressed pseudogenes in the transcriptional landscape of human cancers. Cell (2012) 4.22
The GENCODE pseudogene resource. Genome Biol (2012) 4.18
The multilayered complexity of ceRNA crosstalk and competition. Nature (2014) 4.15
MicroRNAs can generate thresholds in target gene expression. Nat Genet (2011) 3.90
Long non-coding RNAs and cancer: a new frontier of translational research? Oncogene (2012) 3.83
Systematic identification of long noncoding RNAs expressed during zebrafish embryogenesis. Genome Res (2011) 3.81
Diversifying microRNA sequence and function. Nat Rev Mol Cell Biol (2013) 3.80
miRNA-dependent gene silencing involving Ago2-mediated cleavage of a circular antisense RNA. EMBO J (2011) 3.55
MicroRNAs in cancer. Annu Rev Pathol (2013) 3.50
A continuum model for tumour suppression. Nature (2011) 3.48
RNA in unexpected places: long non-coding RNA functions in diverse cellular contexts. Nat Rev Mol Cell Biol (2013) 3.47
MicroRNAs and other non-coding RNAs as targets for anticancer drug development. Nat Rev Drug Discov (2013) 3.33
The imprinted H19 lncRNA antagonizes let-7 microRNAs. Mol Cell (2013) 3.27
MicroRNAs in human cancer. Adv Exp Med Biol (2013) 3.19
Long noncoding RNAs: past, present, and future. Genetics (2013) 3.16
The rise of regulatory RNA. Nat Rev Genet (2014) 3.02
Long noncoding RNAs and the genetics of cancer. Br J Cancer (2013) 2.98
Assessing the ceRNA hypothesis with quantitative measurements of miRNA and target abundance. Mol Cell (2014) 2.83
Detecting and characterizing circular RNAs. Nat Biotechnol (2014) 2.73
A functional genomic approach identifies FAL1 as an oncogenic long noncoding RNA that associates with BMI1 and represses p21 expression in cancer. Cancer Cell (2014) 2.72
Emerging roles for natural microRNA sponges. Curr Biol (2010) 2.62
Transcriptome-wide miR-155 binding map reveals widespread noncanonical microRNA targeting. Mol Cell (2012) 2.54
Convergent multi-miRNA targeting of ApoE drives LRP1/LRP8-dependent melanoma metastasis and angiogenesis. Cell (2012) 2.50
The Pan-Cancer analysis of pseudogene expression reveals biologically and clinically relevant tumour subtypes. Nat Commun (2014) 2.48
Retracted HMGA2 functions as a competing endogenous RNA to promote lung cancer progression. Nature (2013) 2.47
The miR-17/92 cluster: a comprehensive update on its genomics, genetics, functions and increasingly important and numerous roles in health and disease. Cell Death Differ (2013) 2.41
PTEN protein loss by immunostaining: analytic validation and prognostic indicator for a high risk surgical cohort of prostate cancer patients. Clin Cancer Res (2011) 2.35
A pseudogene long-noncoding-RNA network regulates PTEN transcription and translation in human cells. Nat Struct Mol Biol (2013) 2.33
Discovery and validation of a prostate cancer genomic classifier that predicts early metastasis following radical prostatectomy. PLoS One (2013) 2.31
Long non-coding RNA: a new player in cancer. J Hematol Oncol (2013) 2.26
miRcode: a map of putative microRNA target sites in the long non-coding transcriptome. Bioinformatics (2012) 2.13
Integrated transcriptional and competitive endogenous RNA networks are cross-regulated in permissive molecular environments. Proc Natl Acad Sci U S A (2013) 2.13
Obligate ligation-gated recombination (ObLiGaRe): custom-designed nuclease-mediated targeted integration through nonhomologous end joining. Genome Res (2012) 2.12
DNMT1-interacting RNAs block gene-specific DNA methylation. Nature (2013) 2.04
Pseudogenes: pseudo-functional or key regulators in health and disease? RNA (2011) 2.00
Regulation of eukaryotic gene expression by the untranslated gene regions and other non-coding elements. Cell Mol Life Sci (2012) 1.96
PTEN level in tumor suppression: how much is too little? Cancer Res (2011) 1.90
The long intergenic noncoding RNA landscape of human lymphocytes highlights the regulation of T cell differentiation by linc-MAF-4. Nat Immunol (2015) 1.82
Evolutionary conservation of long non-coding RNAs; sequence, structure, function. Biochim Biophys Acta (2013) 1.79
The lncRNA H19 promotes epithelial to mesenchymal transition by functioning as miRNA sponges in colorectal cancer. Oncotarget (2015) 1.78
DNA methylation-associated silencing of tumor-suppressor microRNAs in cancer. Oncogene (2011) 1.76
Rare codons regulate KRas oncogenesis. Curr Biol (2012) 1.74
ceRNA cross-talk in cancer: when ce-bling rivalries go awry. Cancer Discov (2013) 1.74
Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer. Nature (2017) 1.72
Aberrant regulation and function of microRNAs in cancer. Curr Biol (2014) 1.72
fMiRNA-192 and miRNA-204 Directly Suppress lncRNA HOTTIP and Interrupt GLS1-Mediated Glutaminolysis in Hepatocellular Carcinoma. PLoS Genet (2015) 1.69
The human long non-coding RNA-RoR is a p53 repressor in response to DNA damage. Cell Res (2012) 1.66
A mammalian pseudogene lncRNA at the interface of inflammation and anti-inflammatory therapeutics. Elife (2013) 1.63
Long Noncoding RNAs in Cancer Pathways. Cancer Cell (2016) 1.63
Competition between pre-mRNAs for the splicing machinery drives global regulation of splicing. Mol Cell (2013) 1.62
miR-221/222 overexpession in human glioblastoma increases invasiveness by targeting the protein phosphate PTPμ. Oncogene (2011) 1.62
Considerations when investigating lncRNA function in vivo. Elife (2014) 1.61
RNA-Seq of human neurons derived from iPS cells reveals candidate long non-coding RNAs involved in neurogenesis and neuropsychiatric disorders. PLoS One (2011) 1.60
Functional interactions among microRNAs and long noncoding RNAs. Semin Cell Dev Biol (2014) 1.55
Conserved regulation of p53 network dosage by microRNA-125b occurs through evolving miRNA-target gene pairs. PLoS Genet (2011) 1.55
Mechanisms of miRNA-Mediated Gene Regulation from Common Downregulation to mRNA-Specific Upregulation. Int J Genomics (2014) 1.54
On the classification of long non-coding RNAs. RNA Biol (2013) 1.53
Long non-coding RNA in cancer. Int J Mol Sci (2013) 1.52
Transcriptome characterization by RNA sequencing identifies a major molecular and clinical subdivision in chronic lymphocytic leukemia. Genome Res (2013) 1.51
Long non-coding RNA ANRIL (CDKN2B-AS) is induced by the ATM-E2F1 signaling pathway. Cell Signal (2013) 1.50
Long noncoding RNA associated-competing endogenous RNAs in gastric cancer. Sci Rep (2014) 1.50
CCAT2, a novel long non-coding RNA in breast cancer: expression study and clinical correlations. Oncotarget (2013) 1.48
The Landscape of long noncoding RNA classification. Trends Genet (2015) 1.47
PTEN loss defines a PI3K/AKT pathway-dependent germinal center subtype of diffuse large B-cell lymphoma. Proc Natl Acad Sci U S A (2013) 1.44
The complexity of miRNA-mediated repression. Cell Death Differ (2014) 1.44
Analysis of genomic variation in non-coding elements using population-scale sequencing data from the 1000 Genomes Project. Nucleic Acids Res (2011) 1.43
Protein kinase signaling networks in cancer. Curr Opin Genet Dev (2010) 1.41
Genetic and epigenetic stability of human pluripotent stem cells. Nat Rev Genet (2012) 1.38
Identification of a long non-coding RNA as a novel biomarker and potential therapeutic target for metastatic prostate cancer. Oncotarget (2014) 1.38
PTEN Tumor Suppressor Network in PI3K-Akt Pathway Control. Genes Cancer (2010) 1.38
A pathophysiological view of the long non-coding RNA world. Oncotarget (2014) 1.36
Novel classes of non-coding RNAs and cancer. J Transl Med (2012) 1.35
Attenuation of miR-126 activity expands HSC in vivo without exhaustion. Cell Stem Cell (2012) 1.35
MicroRNAs as a selective channel of communication between competing RNAs: a steady-state theory. Biophys J (2013) 1.35
MicroRNA control of epithelial-mesenchymal transition and metastasis. Cancer Metastasis Rev (2012) 1.34
Long non-coding RNAs: versatile master regulators of gene expression and crucial players in cancer. Am J Transl Res (2012) 1.33
MicroRNAs: target recognition and regulatory functions. Cell (2009) 92.17
Identification and analysis of functional elements in 1% of the human genome by the ENCODE pilot project. Nature (2007) 75.09
Prediction of mammalian microRNA targets. Cell (2003) 53.70
Chromatin signature reveals over a thousand highly conserved large non-coding RNAs in mammals. Nature (2009) 35.48
The impact of microRNAs on protein output. Nature (2008) 32.39
Real-time quantification of microRNAs by stem-loop RT-PCR. Nucleic Acids Res (2005) 29.17
MicroRNA sponges: competitive inhibitors of small RNAs in mammalian cells. Nat Methods (2007) 13.94
Complex landscapes of somatic rearrangement in human breast cancer genomes. Nature (2009) 13.45
The colorectal microRNAome. Proc Natl Acad Sci U S A (2006) 11.59
Many roads to maturity: microRNA biogenesis pathways and their regulation. Nat Cell Biol (2009) 11.50
Pseudogene-derived small interfering RNAs regulate gene expression in mouse oocytes. Nature (2008) 10.71
Widespread shortening of 3'UTRs by alternative cleavage and polyadenylation activates oncogenes in cancer cells. Cell (2009) 10.50
Lymphoproliferative disease and autoimmunity in mice with increased miR-17-92 expression in lymphocytes. Nat Immunol (2008) 10.42
MicroRNAs to Nanog, Oct4 and Sox2 coding regions modulate embryonic stem cell differentiation. Nature (2008) 9.83
Target mimicry provides a new mechanism for regulation of microRNA activity. Nat Genet (2007) 9.48
Tenets of PTEN tumor suppression. Cell (2008) 8.61
Integrative analysis of the melanoma transcriptome. Genome Res (2010) 8.46
microRNAs exhibit high frequency genomic alterations in human cancer. Proc Natl Acad Sci U S A (2006) 8.24
Pten dose dictates cancer progression in the prostate. PLoS Biol (2003) 7.62
E2F1-regulated microRNAs impair TGFbeta-dependent cell-cycle arrest and apoptosis in gastric cancer. Cancer Cell (2008) 7.56
MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res (2008) 7.45
MicroRNAs and cancer: short RNAs go a long way. Cell (2009) 7.25
Redirection of silencing targets by adenosine-to-inosine editing of miRNAs. Science (2007) 7.15
Involvement of human micro-RNA in growth and response to chemotherapy in human cholangiocarcinoma cell lines. Gastroenterology (2006) 7.06
P-TEN, the tumor suppressor from human chromosome 10q23, is a dual-specificity phosphatase. Proc Natl Acad Sci U S A (1997) 5.32
miR-24 Inhibits cell proliferation by targeting E2F2, MYC, and other cell-cycle genes via binding to "seedless" 3'UTR microRNA recognition elements. Mol Cell (2009) 5.22
MicroRNA-21 promotes cell transformation by targeting the programmed cell death 4 gene. Oncogene (2008) 4.43
Impaired Fas response and autoimmunity in Pten+/- mice. Science (1999) 4.25
Subtle variations in Pten dose determine cancer susceptibility. Nat Genet (2010) 4.19
The PTEN-regulating microRNA miR-26a is amplified in high-grade glioma and facilitates gliomagenesis in vivo. Genes Dev (2009) 4.15
TGF-beta activates Akt kinase through a microRNA-dependent amplifying circuit targeting PTEN. Nat Cell Biol (2009) 4.05
Role of the proto-oncogene Pokemon in cellular transformation and ARF repression. Nature (2005) 3.75
Biological basis for restriction of microRNA targets to the 3' untranslated region in mammalian mRNAs. Nat Struct Mol Biol (2009) 3.70
Redefining microRNA targets. Curr Biol (2009) 3.37
Transcribed processed pseudogenes in the human genome: an intermediate form of expressed retrosequence lacking protein-coding ability. Nucleic Acids Res (2005) 2.89
A broadly conserved pathway generates 3'UTR-directed primary piRNAs. Curr Biol (2009) 2.69
Oncogenic role of miR-17-92 cluster in anaplastic thyroid cancer cells. Cancer Sci (2008) 2.39
Oct4 pseudogenes are transcribed in cancers. Biochem Biophys Res Commun (2005) 2.34
Quantitative HOX expression in chromosomally defined subsets of acute myelogenous leukemia. Leukemia (2002) 2.29
A 3'-untranslated region (3'UTR) induces organ adhesion by regulating miR-199a* functions. PLoS One (2009) 2.24
Pseudogenes in metazoa: origin and features. Brief Funct Genomic Proteomic (2004) 1.99
The theory of APL revisited. Curr Top Microbiol Immunol (2007) 1.96
Multiple retropseudogenes from pluripotent cell-specific gene expression indicates a potential signature for novel gene identification. J Biol Chem (2005) 1.79
Transcriptional analysis of the PTEN/MMAC1 pseudogene, psiPTEN. Oncogene (1999) 1.72
Comparative analysis of processed ribosomal protein pseudogenes in four mammalian genomes. Genome Biol (2009) 1.71
Novel recurrent genetic imbalances in human hepatocellular carcinoma cell lines identified by comparative genomic hybridization. Hepatology (1999) 1.50
Pseudo-messenger RNA: phantoms of the transcriptome. PLoS Genet (2006) 1.46
Gain of chromosome 17 is the most frequent abnormality detected in neuroblastoma by comparative genomic hybridization. Am J Pathol (1997) 1.44
Allelic imbalance sequencing reveals that single-nucleotide polymorphisms frequently alter microRNA-directed repression. Nat Biotechnol (2009) 1.39
The long and short of inverted repeat genes in animals: microRNAs, mirtrons and hairpin RNAs. Cell Cycle (2008) 1.38
Abundant adrenal-specific transcription of the human P450c21A "pseudogene". J Biol Chem (1993) 1.28
Comparative genomic hybridisation divides retinoblastomas into a high and a low level chromosomal instability group. J Clin Pathol (2003) 1.18
Induction of human serum amyloid A in Hep 3B cells by IL-6 and IL-1 beta involves both transcriptional and post-transcriptional mechanisms. J Immunol (1995) 1.08
Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature (2005) 15.83
Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest (2008) 10.74
A ceRNA hypothesis: the Rosetta Stone of a hidden RNA language? Cell (2011) 10.50
Tenets of PTEN tumor suppression. Cell (2008) 8.61
The MicroRNA miR-124 promotes neuronal differentiation by triggering brain-specific alternative pre-mRNA splicing. Mol Cell (2007) 7.99
Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis. Cell (2005) 7.75
Pten dose dictates cancer progression in the prostate. PLoS Biol (2003) 7.62
The functions and regulation of the PTEN tumour suppressor. Nat Rev Mol Cell Biol (2012) 7.32
Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate. Nat Genet (2009) 7.26
Coding-independent regulation of the tumor suppressor PTEN by competing endogenous mRNAs. Cell (2011) 7.02
Does the ribosome translate cancer? Nat Rev Cancer (2003) 6.89
Essential role for nuclear PTEN in maintaining chromosomal integrity. Cell (2007) 6.52
High-resolution analysis of parent-of-origin allelic expression in the mouse brain. Science (2010) 5.91
Structure, dynamics and functions of promyelocytic leukaemia nuclear bodies. Nat Rev Mol Cell Biol (2007) 5.79
Ubiquitination regulates PTEN nuclear import and tumor suppression. Cell (2007) 5.62
Essential role of Plzf in maintenance of spermatogonial stem cells. Nat Genet (2004) 5.55
NEDD4-1 is a proto-oncogenic ubiquitin ligase for PTEN. Cell (2007) 5.20
In vivo identification of tumor- suppressive PTEN ceRNAs in an oncogenic BRAF-induced mouse model of melanoma. Cell (2011) 5.19
The translation factor eIF-4E promotes tumor formation and cooperates with c-Myc in lymphomagenesis. Nat Med (2004) 5.01
Bethesda proposals for classification of nonlymphoid hematopoietic neoplasms in mice. Blood (2002) 4.88
Nucleophosmin and cancer. Nat Rev Cancer (2006) 4.82
Nuclear PTEN regulates the APC-CDH1 tumor-suppressive complex in a phosphatase-independent manner. Cell (2011) 4.49
Evidence that inositol polyphosphate 4-phosphatase type II is a tumor suppressor that inhibits PI3K signaling. Cancer Cell (2009) 4.30
Subtle variations in Pten dose determine cancer susceptibility. Nat Genet (2010) 4.19
The BTB-zinc finger transcriptional regulator PLZF controls the development of invariant natural killer T cell effector functions. Nat Immunol (2008) 4.15
Identification of the miR-106b~25 microRNA cluster as a proto-oncogenic PTEN-targeting intron that cooperates with its host gene MCM7 in transformation. Sci Signal (2010) 4.15
Role of nucleophosmin in embryonic development and tumorigenesis. Nature (2005) 4.09
The SUMO pathway is essential for nuclear integrity and chromosome segregation in mice. Dev Cell (2005) 3.96
Sex-specific parent-of-origin allelic expression in the mouse brain. Science (2010) 3.89
SUMO modification of Huntingtin and Huntington's disease pathology. Science (2004) 3.85
Sox2 deficiency causes neurodegeneration and impaired neurogenesis in the adult mouse brain. Development (2004) 3.75
Role of the proto-oncogene Pokemon in cellular transformation and ARF repression. Nature (2005) 3.75
PML targeting eradicates quiescent leukaemia-initiating cells. Nature (2008) 3.75
SIRT3 opposes reprogramming of cancer cell metabolism through HIF1α destabilization. Cancer Cell (2011) 3.71
Identification of a tumour suppressor network opposing nuclear Akt function. Nature (2006) 3.68
Requirement for caspase-8 in NF-kappaB activation by antigen receptor. Science (2005) 3.64
The deubiquitinylation and localization of PTEN are regulated by a HAUSP-PML network. Nature (2008) 3.53
PI3K pathway regulates survival of cancer stem cells residing in the perivascular niche following radiation in medulloblastoma in vivo. Genes Dev (2008) 3.50
A continuum model for tumour suppression. Nature (2011) 3.48
A novel type of cellular senescence that can be enhanced in mouse models and human tumor xenografts to suppress prostate tumorigenesis. J Clin Invest (2010) 3.47
A PML–PPAR-δ pathway for fatty acid oxidation regulates hematopoietic stem cell maintenance. Nat Med (2012) 3.33
The role of PML in tumor suppression. Cell (2002) 3.28
A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response. Nature (2012) 3.24
Cannabinoid action induces autophagy-mediated cell death through stimulation of ER stress in human glioma cells. J Clin Invest (2009) 3.23
The mechanisms of PML-nuclear body formation. Mol Cell (2006) 3.22
PML regulates apoptosis at endoplasmic reticulum by modulating calcium release. Science (2010) 3.21
Genome-wide lineage-specific transcriptional networks underscore Ikaros-dependent lymphoid priming in hematopoietic stem cells. Immunity (2009) 3.18
Dyskeratosis congenita and cancer in mice deficient in ribosomal RNA modification. Science (2003) 3.18
Loss of the tumor suppressor PML in human cancers of multiple histologic origins. J Natl Cancer Inst (2004) 3.17
eIF4E phosphorylation promotes tumorigenesis and is associated with prostate cancer progression. Proc Natl Acad Sci U S A (2010) 3.13
Skp2 targeting suppresses tumorigenesis by Arf-p53-independent cellular senescence. Nature (2010) 3.09
High frequency of PTEN, PI3K, and AKT abnormalities in T-cell acute lymphoblastic leukemia. Blood (2009) 3.02
PML inhibits HIF-1alpha translation and neoangiogenesis through repression of mTOR. Nature (2006) 3.01
Generation of functional multipotent adult stem cells from GPR125+ germline progenitors. Nature (2007) 3.01
Absence of nucleolar disruption after impairment of 40S ribosome biogenesis reveals an rpL11-translation-dependent mechanism of p53 induction. Nat Cell Biol (2009) 2.97
A CK2-dependent mechanism for degradation of the PML tumor suppressor. Cell (2006) 2.95
Regulation of B versus T lymphoid lineage fate decision by the proto-oncogene LRF. Science (2007) 2.92
Phosphorylation-dependent regulation of cytosolic localization and oncogenic function of Skp2 by Akt/PKB. Nat Cell Biol (2009) 2.91
Cytoplasmic PML function in TGF-beta signalling. Nature (2004) 2.89
Eradication of acute promyelocytic leukemia-initiating cells through PML-RARA degradation. Nat Med (2008) 2.85
The deficiency of Akt1 is sufficient to suppress tumor development in Pten+/- mice. Genes Dev (2006) 2.76
Pro-senescence therapy for cancer treatment. Nat Rev Cancer (2011) 2.75
PML, YAP, and p73 are components of a proapoptotic autoregulatory feedback loop. Mol Cell (2008) 2.66
Cancer metabolism: fatty acid oxidation in the limelight. Nat Rev Cancer (2013) 2.59
Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for BRCA1-related breast cancer. Cancer Discov (2012) 2.53
Effect of angiogenesis inhibition by Id loss and the contribution of bone-marrow-derived endothelial cells in spontaneous murine tumors. Cancer Cell (2003) 2.53
A novel signal transduction cascade involving direct physical interaction of the renin/prorenin receptor with the transcription factor promyelocytic zinc finger protein. Circ Res (2006) 2.50
PML regulates p53 stability by sequestering Mdm2 to the nucleolus. Nat Cell Biol (2004) 2.45
PML is a direct p53 target that modulates p53 effector functions. Mol Cell (2004) 2.40
Systemic elevation of PTEN induces a tumor-suppressive metabolic state. Cell (2012) 2.39
The oncogenic microRNA miR-22 targets the TET2 tumor suppressor to promote hematopoietic stem cell self-renewal and transformation. Cell Stem Cell (2013) 2.33
Promyelocytic leukemia protein mediates interferon-based anti-herpes simplex virus 1 effects. J Virol (2003) 2.33
A co-clinical approach identifies mechanisms and potential therapies for androgen deprivation resistance in prostate cancer. Nat Genet (2013) 2.29
Plzf regulates germline progenitor self-renewal by opposing mTORC1. Cell (2010) 2.29
Improved clinical outcomes with high-dose image guided radiotherapy compared with non-IGRT for the treatment of clinically localized prostate cancer. Int J Radiat Oncol Biol Phys (2012) 2.28
Lats2/Kpm is required for embryonic development, proliferation control and genomic integrity. EMBO J (2004) 2.18
Tsc2-Rheb signaling regulates EphA-mediated axon guidance. Nat Neurosci (2010) 2.17
Activation of Akt/protein kinase B overcomes a G(2)/m cell cycle checkpoint induced by DNA damage. Mol Cell Biol (2002) 2.15
TCR-inducible PLZF transcription factor required for innate phenotype of a subset of gammadelta T cells with restricted TCR diversity. Proc Natl Acad Sci U S A (2009) 2.13
Critical role for lysyl oxidase in mesenchymal stem cell-driven breast cancer malignancy. Proc Natl Acad Sci U S A (2012) 2.13
Integrated transcriptional and competitive endogenous RNA networks are cross-regulated in permissive molecular environments. Proc Natl Acad Sci U S A (2013) 2.13
The AKT-mTOR pathway plays a critical role in the development of leiomyosarcomas. Nat Med (2007) 2.12
Causality and Chance in the Development of Cancer. N Engl J Med (2015) 2.10
mTOR promotes survival and astrocytic characteristics induced by Pten/AKT signaling in glioblastoma. Neoplasia (2005) 2.04
PTEN and TNF-alpha regulation of the intestinal-specific Cdx-2 homeobox gene through a PI3K, PKB/Akt, and NF-kappaB-dependent pathway. Gastroenterology (2002) 2.03
Genetic analysis of Pten and Tsc2 functional interactions in the mouse reveals asymmetrical haploinsufficiency in tumor suppression. Genes Dev (2005) 1.99
Identification of S664 TSC2 phosphorylation as a marker for extracellular signal-regulated kinase mediated mTOR activation in tuberous sclerosis and human cancer. Cancer Res (2007) 1.94